ImmunityBio, Inc.
ImmunityBio Reports 60% Increase in Q2 2025 Revenue with Positive Clinical Trial Updates
Summary
ImmunityBio, Inc. reported a 60% increase in Q2 2025 revenue to $26.4 million, with year-to-date sales of $43 million, driven by the commercial traction of ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer. The company ended Q2 with $153.7 million in cash, cash equivalents, and marketable securities. Additionally, ImmunityBio presented positive updates from its clinical trials, including meeting with the FDA regarding lymphopenia and receiving marketing authorization for ANKTIVA in the UK for BCG-unresponsive non-muscle invasive bladder cancer.
Profitelligence Alerts
Get alerts for IBRX
Be first to know when ImmunityBio, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About ImmunityBio, Inc.
ImmunityBio, Inc. is a pioneering biotechnology company that focuses on developing innovative immunotherapies to treat cancer and other serious diseases. The company's primary function is to leverage the body's immune system to fight against various forms of cancer as well as infectious diseases through a robust pipeline of therapies. ImmunityBio's notable features include its expansive portfolio of next-generation therapies that incorporate cutting-edge technologies, such as the NANT Cancer Vaccine and Anktiva, which are designed to enhance the immune system's natural ability to identify and eradicate tumor cells. The company plays a critical role in the healthcare and biotechnology sectors, contributing to advancements in personalized medicine and potentially transformative treatments. Headquartered in California, ImmunityBio is strategically placed in the biotechnology hub of the United States, allowing it to effectively collaborate with key players in research and clinical development. Its work is significant in the market as it represents the ongoing shift towards immunotherapy as a front-line treatment for cancer, promising to impact patient outcomes and the future of cancer care.
Official SEC Documents
Advertisement